USP-NF Publishes Notice of Intent to Revise General Chapter <711> Dissolution

Recommendation
Wednesday, 1 October 2025 13.00 - 17.00 h
In a USP–NF Compendial Notice published 29 October 2021, it was announced that the Dosage Forms Expert Committee intends to revise General Chapter <711> Dissolution. It is anticipated that the proposed revision will be published as an Interim Revision Announcement (IRA) in Pharmacopeial Forum 48(2) in March 2022, with the comment period ending on 31 May 2022. Thus, the revision may become official as early as on 01 September 2022.
"The purpose of this revision is to include an option for using a new USP Reference Standard, Dissolution Performance Verification Standard – Prednisone, to qualify the Dissolution Apparatus 1 (basket) and Dissolution Apparatus 2 (paddle), in addition to the existing USP Reference Standard Prednisone Tablets which is included in the current Chapter."
According to the Notice, the new reference standard will be more sensitive to operational and mechanical variables of instrument setup, less sensitive to media degassing, and more reproducible.
For further information, please see the Notice of Intent to Revise published on the USP-NF website.
Related GMP News
14.07.2025Inadequate Sampling and Component Testing Highlighted in FDA Warning Letter
14.07.2025EMA publishes new Product-Specific Bioequivalence Guidance
14.07.2025Revision of USP Chapter <1039> Chemometrics Published for Comments
14.07.2025Proposal for new USP Chapter <318> NMR Monomer Ratio Determination for Lactide-Glycolide Polymers
14.07.2025New USP Chapter <1221> on Ongoing Procedure Performance Verification (OPPV) Published for Comment
02.07.2025FDA Warning Letter: Missing Testing, No Stability Data, and Inadequate Raw Material Controls